EOD v1.4 known issues:

These changes will not be implemented until 2019.

9/13/2018

  • Pancreas: EOD Mets code 70 should contribute ā€˜Dā€™ to the Derived SS2018, but currently is ā€˜Uā€™. This results in a Derived SS2018 other than 7.
  • Thyroid Medullary: In EOD Primary Tumor, Microscopic extrathyroidal extension is not mentioned. Codes 200 and 300 are being reviewed.

9/24/2018

  • Colon and Rectum:
    • KRAS Note 4 changed to be "Results from nodal or metastatic tissue may be used for KRAS."
    • Perineural Invasion needs a Note 4: "If no mention of perineural invasion, cannot assume negative (code 9 for unknown)"
  • Vagina, Vulva: LN Assessment Method Femoral-Inguinal, LN Assessment Method Para-Aortic and LN Assessment Method Pelvic all need a Note 3 describing how to handle there being no mention of the specific lymph node involvement and the Status data item doesn't indicate positive nodes of that type (code 0).



EOD v1.4 changes:

  • Bile Ducts Intrahepatic, Liver: Fibrosis Score Note 2 from v1.3 was replaced with Notes 4-6 to provide more information about the coding of this item
  • Bladder, Kidney Renal Pelvis, Urethra, Urethra-Prostatic:
    • Grade Clinical, Grade Pathological, Grade Post Therapy: Notes about priority order were expanded for clarity
    • Grade Clinical and Grade Pathological: Note was added that for bladder, TURB does not qualify for surgical resection and is considered clinical only
  • Brain, CNS Other, Intracranial Gland and Orbital Sarcoma, Soft Tissue Head and Neck, Soft Tissue Other:
    • Sites C700-C729, C751-C753 with histologies 9380-9539 were moved for all behaviors (0, 1 and 3) from sacroma schemas into the brain related schemas. This EXCLUDES any combinations specifically mentioned by AJCC as eligible for staging in the sacroma chapters.
  • Colon and Rectum:
    • KRAS: Note 4 and 5 were added to describe where information can be gathered from
    • Perineural Invasion: Note 3 was modified to clarify where information can be obtained from
    • Microsatellite Instability: Note 2 (describing what MSI testing is) and Note 3 (describing how such testing is done) were modified. Note 4 (about terms used in Canada) was removed.
  • Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck: Schema Discriminator 1 Notes were revised to improve clarity regarding how this item is to be assigned
  • Cutaneous Squamous Cell Carcinoma of Head and Neck:
    • The schema name was changed to be Cutaneous Carcinoma of Head and Neck
    • References to Chapter 15 (Cutaneous Carcinoma of Head and Neck) were changed to remove "Squamous Cell" from chapter name
    • The determination of EOD Derived T based on Tumor Size was updated to synchronize with AJCC changes from 2/2/2018 to T1, T2 and T3
    • High Risk Histologic Features: Note 3 was modified to clarify where information can be obtained from
  • Esophagus: EOD Primary Tumor Note 1 code related to submucosal was corrected to be 150
  • Head and Neck related schemas: EOD Regional Nodes was updated to synchronize with AJCC changes from 2/2/2018 to pN3, pN3b, ypN3 and ypN3b ("a single contralateral node of any size and ENE(+)")
  • Hypopharynx: EOD Primary Tumor code 300 was changed to specify Esophageal mucosa, code 400 was changed to specify Esophageal muscle
  • Liver:
    • Bilirubin Pretreatment Total Lab Values Note 3 was revised to indicate that Total Lab Values include conjugated, unconjugated and total bilirubin values
    • Creatinine Pretreatment Unit of Measure [3825] was changed to reflect that is is only required by SEER if CoC collects the case (as is lab value)
  • Lymphoma CLL/SLL: Anemia Note 3 was revised to include hemoglobin & hematocrit, H&H as test types
  • Melanoma Skin: EOD Regional Nodes code 700 was updated to provide more information for two or more clinically occult or detected nodes
  • Oral Cavity (Chapter 7) related schemas:
    • References to Chapter 7 (Oral Cavity) were changed to remove "Lip and" from chapter name
    • The determination of EOD Derived T based on EOD Primary Tumor and Depth of Invasion was updated to synchronize with AJCC changes from 5/25/2018 related to T1, T2, T3 and T4a
    • SEER SSF1 [3700]: Human Papilloma Virus (HPV) Status was modified to remove the SSDI flag
    • Extranodal Extension Head and Neck Clinical [3831]: Notes 5 and 6 were revised to improve clarity of coding rules
  • Ovary:
    • EOD Primary Tumor, Note 6 exceptions to large intestine were changed to include "(except rectum, rectosigmoid and sigmoid colon)"
    • EOD Primary Tumor, Code 750 modified to remove requirement of microscopic confirmation
  • Plasma Cell Myeloma and Plasma Cell Disorders: The AJCC ID was changed so that Plasma Cell Myeloma is 82.1 and Plasma Cell Disorders is 82.2
  • Primary Cutaneous Lymphoma: EOD Primary Tumor codes 400 and 500 were added to address the addition of T3a and T3b to AJCC T (2/2/2018)
  • Prostate:
    • Prostate Path Extension [3919] is no longer flagged as an SSDI. This is an EOD field.
    • Grade Clinical and Grade Pathological: Note added to indicate that TURP does not qualify for surgical resection and is considered clinical only
  • Thyroid: EOD Regional Nodes, code 300 was modified to add Level VII-Superior mediastinal group
  • General
    • Grade Clinical: Note about only one grade available was revised. If cannot determine if clinical or pathological, assume it is clinical and code appropriately per clinical grade categories.
    • Grade Pathological: Note about highest grade was revised to clarify statement about using clinical grade if it is the highest. This follows the AJCC rule that pathological time frame includes all clinical time frame information plus information from the resected specimen. Example situations provided where resection is done but either no grade is documented or there was no residual cancer.
    • Grade Post Therapy: Note about Code 9 had bullet added for "Surgical resection is done after neoadjuvant therapy and there is no residual cancer"
    • Adjustments were made to calculation tables to handle DCO cases not having SSDI values
    • Adjusted NPCR required fields to match the Updated REQ Data Item List for Summ Stage Only (EXCEL) from the "Update from CDC-NPCR on 2018 Changes" as sent by Vicki Benard
    • Tumor Size Clinical, Pathological, and Summary: for those schema where 999 is the only valid value, the lookup was limited to 999. 998 was removed from schemas where it does not apply.
    • LVI was added to all schema. Prostate and Testis lookup does not include 8. Schemas that can only be 8 have a lookup with only that value.
    • Searched and replaced quotes and dashes from Microsoft Word with standard characters